Novo Nordisk AS News

Chris is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

War is brewing in the multibillion-dollar diabetes market. In particular, a major skirmish will soon be fought over which insulin products will emerge as victors in a changing landscape.

Denmark's Novo Nordisk , the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss.

Novo Resources Corp. is pleased to announce that it has filed a technical report prepared pursuant to National Instrument 43-101 related to its May 1, 2013 news release announcing the maiden resource estimate for its Beatons Creek Gold Project, Western Australia.

Can oral insulin succeed where other alternative delivery methods have failed? Dan Stanton, from in-Pharmatechnologist.com assesses its chances.

Xellia is a leading developer and manufacturer of anti-infective therapies for multi-drug resistant infections.

Bagsvaerd, Denmark, - Novo Nordisk today announced the completion of paradigmTM 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP , for haemophilia B patients.

Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP. Novo Nordisk said in a statement that in patients given the drug, 99 percent of bleeding episodes were treated with only one infusion and two-thirds of the patients had experienced complete resolution ... (more)

's earnings were better than expected. It is one of the few medical companies that is able to deliver organic growth in a challenged healthcare industry.

Tyler is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

Novo Nordisk announced that a new survey of women on local estrogen therapy revealing key insights into reasons for treatment non-compliance was published in the International Journal of Women's Health .

Novo Nordisk says the $69 investment in its Danish plant will convert capacity ready for its new GLP-1 analogue and is a further commitment to Danish manufacturing.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today that it closed an expansion of its previously announced 100 million financing, attaining a total of a 141 million placement of preferred stock to a group of existing investors.

Top Stories Fed doves to fly. Economists expect the Fed to exhibit a more somber tone on the U.S. economy and the outlook for the nascent recovery when the FOMC wraps up its two-day policy meeting today.

Jesper Brandgaard - Chief Financial Officer, Executive Vice President, Member of the Senior Management Board, Chairman of Novo Nordisk Engineering A/S and Chairman of Novo Nordisk IT A/S Good day, and welcome to Q1 2013 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk issued its quarterly earnings data on Wednesday. The company reported $10.98 earnings per share for the quarter, beating the analysts' consensus estimate of $10.67 by $0.31, Stock Ratings Network reports.

Price increases on cable TV helped boost numbers, as subscribers paid an average of $3.40 more per month compared with the same period last year.

Novo Resources Corp. is pleased to announce the first ever National Instrument 43-101 compliant resource estimate for its Beatons Creek Gold Project, Western Australia.

Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday.